SAB Biotherapeutics Statistics
NASDAQ: SABSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
2.81-0.10 (-3.44%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SAB Biotherapeutics by the numbers
SAB Biotherapeutics has a market capitalization of $253.1 million based on 90.09M shares outstanding. With trailing EPS of $-1.35, SAB Biotherapeutics is unprofitable on a 12-month basis, so earnings-based valuation ratios do not apply. The stock trades 8.4% below its 50-day average and 21.9% below its 200-day average.
Average daily trading volume is 633.60K shares, or about $1.8 million in dollar volume.
Summary generated from market data by MetaCap's automated system. Methodology
SABS valuation vs. peer median
| Metric | SABS | Peer median | Difference |
|---|---|---|---|
| Market cap | $253.15M | $254.98M | -1% |
| Avg. volume | 633.60K | 1.44M | -56% |
Peer median across 8 companies: EDIT, EIKN, OCGN, LXEO, PLX, AUTL, AGMB, KYTX.
Valuation
- Market cap
- $253.15M
- EPS (TTM)
- $-1.35
- Shares outstanding
- 90.09M
Price and trading
- Previous close
- 2.91
- Open
- 2.79
- Day range
- 2.64 – 2.88
- 52-week range
- 2.44 – 5.15
- 52-week change
- -28.86%
- Beta
- —
- Volume
- 874.57K
- Average volume
- 633.60K
Dividends and events
- Annual dividend
- None
- Next earnings date
- Nov 5, 2026
Additional statistics
- Market Cap
- 253.15M
- Forward Pe
- -2.98
- Eps
- -1.35
- Dividend Yield
- 0.00%
- Dividend Rate
- 0.00
- Week52 High
- 5.15
- Week52 Low
- 2.44
- Avg Volume
- 633.60K
- Shares Outstanding
- 90.09M
- Ma50
- 3.07
- Ma200
- 3.60
- Earnings Date
- Nov 5, 2026
- Pct From52w High
- -45.44%
- Pct From52w Low
- 15.16%